This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): oseltamivir phosphate
Description: Tamiflu is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of Tamiflu is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.
Deal Structure: Tamiflu is sold by Gilead's corporate partner Hoffmann-La Roche (Roche) in more than 60 countries, including the U.S. and the European Union.
In September 1996, Gilead and F. Hoffmann-La Roche Ltd. entered into a collaborative agreement to develop and market therapies that treat and prevent viral influenza. Under the agreement, Roche received exclusive worldwide rights to Gilead's proprietary influenza neuraminidase inhibitors, including orally administered Tamiflu. As part of this collaboration, Gilead and Roche jointly conducted clinical development of Tamiflu, with Roche funding all research and development costs.
Roche has worldwide commercial rights to Tamiflu, and Gilead receives payments from Roche for the successful completion of program milestones and royalties on product sales.
The royalties payable to Gilead on net sales of Tamiflu sold by Roche remain the same under the amended agreement, which are as follows: (a) 14% of the first $200.0 million in worldwide net...See full deal structure in Biomedtracker
Partners: Gilead Sciences, Inc. Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: